A kinase-inactive type II TGFβ receptor impairs BMP signaling in human breast cancer cells

Nancy Dumont, Carlos L. Arteaga

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Dominant negative receptor mutants are often utilized in order to abrogate signaling induced by growth factors. We have previously shown that expression of a dominant negative type II TGFβ receptor (dnTβRII) in MDA-MB-231 breast cancer cells effectively abrogates TGFβ signaling. In this letter, we report that expression of dnTβRII also impairs BMP2-mediated Smad1 phosphorylation as well as BMP2-mediated Smad-dependent transcriptional responses, resulting in an attenuation of BMP-mediated anti-proliferative effects. The fact that dnTβRII not only abrogates TGFβ signaling but BMP signaling as well has important implications for the interpretation of data in which dominant negative mutants are utilized.

Original languageEnglish (US)
Pages (from-to)108-112
Number of pages5
JournalBiochemical and Biophysical Research Communications
Volume301
Issue number1
DOIs
StatePublished - Jan 31 2003

Fingerprint

Bone Morphogenetic Protein Receptors
Intercellular Signaling Peptides and Proteins
Phosphotransferases
Cells
Phosphorylation
Breast Neoplasms

Keywords

  • Bone morphogenetic protein
  • Dominant negative type II TGFβ receptor
  • Signaling, MDA-MB-231
  • Transforming growth factor-β

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

A kinase-inactive type II TGFβ receptor impairs BMP signaling in human breast cancer cells. / Dumont, Nancy; Arteaga, Carlos L.

In: Biochemical and Biophysical Research Communications, Vol. 301, No. 1, 31.01.2003, p. 108-112.

Research output: Contribution to journalArticle

@article{d5298668f2ce4e3698c52179b395a721,
title = "A kinase-inactive type II TGFβ receptor impairs BMP signaling in human breast cancer cells",
abstract = "Dominant negative receptor mutants are often utilized in order to abrogate signaling induced by growth factors. We have previously shown that expression of a dominant negative type II TGFβ receptor (dnTβRII) in MDA-MB-231 breast cancer cells effectively abrogates TGFβ signaling. In this letter, we report that expression of dnTβRII also impairs BMP2-mediated Smad1 phosphorylation as well as BMP2-mediated Smad-dependent transcriptional responses, resulting in an attenuation of BMP-mediated anti-proliferative effects. The fact that dnTβRII not only abrogates TGFβ signaling but BMP signaling as well has important implications for the interpretation of data in which dominant negative mutants are utilized.",
keywords = "Bone morphogenetic protein, Dominant negative type II TGFβ receptor, Signaling, MDA-MB-231, Transforming growth factor-β",
author = "Nancy Dumont and Arteaga, {Carlos L.}",
year = "2003",
month = "1",
day = "31",
doi = "10.1016/S0006-291X(02)02977-7",
language = "English (US)",
volume = "301",
pages = "108--112",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A kinase-inactive type II TGFβ receptor impairs BMP signaling in human breast cancer cells

AU - Dumont, Nancy

AU - Arteaga, Carlos L.

PY - 2003/1/31

Y1 - 2003/1/31

N2 - Dominant negative receptor mutants are often utilized in order to abrogate signaling induced by growth factors. We have previously shown that expression of a dominant negative type II TGFβ receptor (dnTβRII) in MDA-MB-231 breast cancer cells effectively abrogates TGFβ signaling. In this letter, we report that expression of dnTβRII also impairs BMP2-mediated Smad1 phosphorylation as well as BMP2-mediated Smad-dependent transcriptional responses, resulting in an attenuation of BMP-mediated anti-proliferative effects. The fact that dnTβRII not only abrogates TGFβ signaling but BMP signaling as well has important implications for the interpretation of data in which dominant negative mutants are utilized.

AB - Dominant negative receptor mutants are often utilized in order to abrogate signaling induced by growth factors. We have previously shown that expression of a dominant negative type II TGFβ receptor (dnTβRII) in MDA-MB-231 breast cancer cells effectively abrogates TGFβ signaling. In this letter, we report that expression of dnTβRII also impairs BMP2-mediated Smad1 phosphorylation as well as BMP2-mediated Smad-dependent transcriptional responses, resulting in an attenuation of BMP-mediated anti-proliferative effects. The fact that dnTβRII not only abrogates TGFβ signaling but BMP signaling as well has important implications for the interpretation of data in which dominant negative mutants are utilized.

KW - Bone morphogenetic protein

KW - Dominant negative type II TGFβ receptor

KW - Signaling, MDA-MB-231

KW - Transforming growth factor-β

UR - http://www.scopus.com/inward/record.url?scp=0037474525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037474525&partnerID=8YFLogxK

U2 - 10.1016/S0006-291X(02)02977-7

DO - 10.1016/S0006-291X(02)02977-7

M3 - Article

C2 - 12535648

AN - SCOPUS:0037474525

VL - 301

SP - 108

EP - 112

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1

ER -